Back

Comparison of Antibody Levels in Response to SARS-CoV-2 Infection and Vaccination Type in a Midwestern Cohort

Remy, L.; Tomomori-Sato, C.; Conkright-Fincham, J.; Wiedemann, L. M.; Conaway, J. W.; Unruh, J. R.

2021-08-29 allergy and immunology
10.1101/2021.08.16.21262036 medRxiv
Show abstract

We present preliminary data in an ongoing observational study reporting SARS-CoV-2 spike protein reactive antibody levels from a convenience cohort of over 250 individuals in Kansas City. We observe stable antibody levels over one year in individuals who recovered from COVID19 infection caused by SARS-CoV-2. By comparison, our data reveals even higher antibody levels from naive individuals vaccinated with Pfizer or Moderna vaccines and slightly lower levels from Johnson & Johnson (J&J) recipients. For all vaccines, inoculation after recovery resulted in higher antibody levels than vaccination alone. Responses to Pfizer and Moderna vaccines decreased over time from high initial levels but at the time of publication remain higher than those for recovered or J&J recipients. Within our limited cohort we only see slight demographic trends including higher antibody levels in recovered female vs. male individuals. Booster doses and breakthrough infections both result in rapid increases in antibody levels.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.